Nathan Fowler, MD, is an Associate Professor in the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer Center.

Dr Fowler received his MD and completed his residency at the University of Texas Medical Branch. He then completed a Clinical Fellowship in Hematology/Oncology at Georgetown University, where he went on to become a Chief Fellow before moving to the MD Anderson Cancer Center in 2007.

Dr Fowler has a long-standing interest in immunomodulatory agents, having helped develop some of the original protocols utilizing lenalidomide for CLL. The aim of his clinical research is to continue the advancement of novel immunomodulatory regimens for patients with non-Hodgkin lymphoma. He is the Chairman of a number of Phase I and II trials in this area and serves as an Advisor for the Clinical Research Advisory Committee. This work has culminated in >2,300 citations of articles that Dr Fowler has authored or co-authored with research groups around the world since 2008.

Alongside this work, Dr Fowler has a strong social media presence, communicating updates in hematology through his Twitter.